Footnote F1 (shares): Certain of these shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger… Full note on SEC EDGAR
Footnote F2 (price): In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration.
Footnote F3 (price): At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of… Full note on SEC EDGAR
Footnote F1 (shares): Certain of these shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger… Full note on SEC EDGAR
Footnote F2 (price): In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration.
Footnote F3 (price): At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of… Full note on SEC EDGAR
Footnote F1 (shares): Certain of these shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger… Full note on SEC EDGAR
Footnote F2 (price): In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration.
Footnote F3 (price): At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of… Full note on SEC EDGAR
Footnote F1 (shares): Certain of these shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger… Full note on SEC EDGAR
Footnote F2 (price): In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration.
Footnote F3 (price): At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of… Full note on SEC EDGAR
Footnote F1 (shares): These shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc… Full note on SEC EDGAR
Footnote F2 (price): In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration.
Footnote F3 (price): At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of… Full note on SEC EDGAR
Footnote F1 (shares): Certain of these shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger… Full note on SEC EDGAR
Footnote F2 (price): In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration.
Footnote F3 (price): At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of… Full note on SEC EDGAR
Footnote F1 (shares): These shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc… Full note on SEC EDGAR
Footnote F2 (price): In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration.
Footnote F3 (price): At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of… Full note on SEC EDGAR
Footnote F1 (shares): Certain of these shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger… Full note on SEC EDGAR
Footnote F2 (price): In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration.
Footnote F3 (price): At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of… Full note on SEC EDGAR
Footnote F1 (shares): Certain of these shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger… Full note on SEC EDGAR
Footnote F2 (price): In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration.
Footnote F3 (price): At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of… Full note on SEC EDGAR
Footnote F4 (price): At the effective time of the Merger, this warrant was cancelled in exchange for a cash payment equal to (i) the product of 1,333 warrant shares multiplied by the Merger Consideration minus (ii) the $4.50 per share exercise price of the warrant.
Footnote F1 (price, shares): These shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc… Full note on SEC EDGAR
Footnote F1 (price, shares): These shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc… Full note on SEC EDGAR
Footnote F2 (price): At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of… Full note on SEC EDGAR
Footnote F1 (shares): Certain of these shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger… Full note on SEC EDGAR
Footnote F2 (price): In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration.
Footnote F1 (shares): Certain of these shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger… Full note on SEC EDGAR
Footnote F2 (price): In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration.
Footnote F3 (price): At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of… Full note on SEC EDGAR
Footnote F2 (price): This transaction was executed in multiple trades at prices ranging from $29.54 to $30.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the… Full note on SEC EDGAR
Footnote F4 (price): This transaction was executed in multiple trades at prices ranging from $30.545 to $31.41. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the… Full note on SEC EDGAR
Footnote F5 (price): This transaction was executed in multiple trades at prices ranging from $31.64 to $31.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the… Full note on SEC EDGAR
Footnote F2 (price): This transaction was executed in multiple trades at prices ranging from $29.54 to $30.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the… Full note on SEC EDGAR
Footnote F4 (price): This transaction was executed in multiple trades at prices ranging from $30.545 to $31.41. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the… Full note on SEC EDGAR
Footnote F5 (price): This transaction was executed in multiple trades at prices ranging from $31.64 to $31.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the… Full note on SEC EDGAR
Footnote F1 (shares): These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 25% of RSUs shall vest on each of March 2, 2027, March 2, 2028, March 2, 2029 and March 2, 2030, subject to the Reporting Person continuing to be a… Full note on SEC EDGAR
Footnote F1 (shares): These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 100% of the RSUs shall vest on December 15, 2027, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's… Full note on SEC EDGAR
Footnote F1 (shares): These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 100% of the RSUs shall vest on December 15, 2027, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's… Full note on SEC EDGAR
Footnote F1 (shares): These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 100% of the RSUs shall vest on December 15, 2027, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's… Full note on SEC EDGAR
Footnote F1 (shares): These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 100% of the RSUs shall vest on December 15, 2027, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's… Full note on SEC EDGAR
Footnote F1 (shares): These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 100% of the RSUs shall vest on December 15, 2027, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's… Full note on SEC EDGAR
Footnote F1 (shares): These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 100% of the RSUs shall vest on December 15, 2027, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's… Full note on SEC EDGAR
Footnote F1 (shares): These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 100% of the RSUs shall vest on December 15, 2027, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's… Full note on SEC EDGAR
Footnote F1 (shares): These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 100% of the RSUs shall vest on December 15, 2027, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's… Full note on SEC EDGAR
Footnote F1 (shares): These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. One-half of the RSUs shall vest on November 17, 2026 and one third of the remaining RSUs shall vest each one-year anniversary thereafter, subject to… Full note on SEC EDGAR
Footnote F1 (shares): These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. One-half of the RSUs shall vest on November 10, 2026 and one third of the remaining RSUs shall vest each one-year anniversary thereafter, subject to… Full note on SEC EDGAR
Footnote F1 (shares): These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. One-third of the RSUs shall vest on October 13, 2026 and each one-year anniversary thereafter, subject to the Reporting Person continuing to be a… Full note on SEC EDGAR
SOLENO THERAPEUTICS INC (SLNO) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-05-18. The full record for SLNO runs to 32 Form 4 filings, the earliest from 2024-10-03. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying SLNO stock?
No insider purchases of SLNO were filed in the last 90 days.
How many insiders are selling SLNO stock?
No insider sales of SLNO were filed in the last 90 days. 15 sales are on record for this company.
Where can I see SLNO SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects SLNO Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Michael F. Huang - OfficerOpen-market sale$128K
Birgitte Volck
Jennifer Fulk - Officer
